de novo


Also found in: Dictionary, Thesaurus, Legal, Wikipedia.
Related to de novo: De novo mutation, De novo review

de no·vo

(di nō'vō),
Anew; often applied to particular biochemical pathways in which metabolites are newly biosynthesized (for example, de novo purine biosynthesis).
[L.]

de novo

(dē nō′vō, dā, nō′wō)
1. Over again from the beginning; anew.
2. Previously undetected.
3. Previously untreated.
References in periodicals archive ?
The 510(k) process allows for a 90 day review period while the de novo process has a 120 day review cycle.
In 2011, the FDA released a draft guidance document proposing to allow sponsors to simultaneously submit 510(k) and de novo submissions, thus eliminating the sequential portion of the process.
While these studies have advanced our knowledge of the overall prevalence of de novo SUI, the risk prediction for a specific patient varies based on individual characteristics.
Leveraging a long history of excellence in Flow Cytometry data analysis, De Novo Software launched FCS Express 4 Image Cytometry in January of 2011.
All applications in response to this RFA, whether to develop resequencing or de novo sequencing technologies, must propose achieving per-base quality at least to this standard.
Our computational and experimental proteomics technologies coupled with De Novo Pharmaceuticals' powerful drug design algorithms, extends our capabilities by linking structure and function information to drug activity.
Peck said plaintiff attorneys might still be able to avoid de novo review after the Cooper Industries decision by seeking specific jury findings that support the punitive award.
The agreement with SBI will allow De Novo to expand its Drug Design Partnerships with early-stage genomics targets.
De Novo Enzyme Corporation is a privately owned spin-off of Simon Fraser University.
As shown in figure 1, panel A, over 3,000 de novo commercial banks have been chartered by state and federal banking authorities since 1980.
The de novo firms were selected in manufacturing, trade and services, while "socially" owned and privatised enterprises were selected from the manufacturing branches.
The court rejected the position of several former employees that the issue of partial termination was a question of law and therefore subject to de novo review by the court.